Abdel-Nabi H, Doerr R J
Department of Nuclear Medicine, State University of New York, Buffalo 14214.
Semin Nucl Med. 1993 Apr;23(2):99-113. doi: 10.1016/s0001-2998(05)80091-1.
During the past two decades, the in vivo application of monoclonal antibodies (MoAbs) in cancer diagnosis and therapy have been widely studied. This can be related to three main factors: (1) dramatic improvement in monoclonal antibody production, revolutionized by Kohler and Milstein; (2) improvement in radioisotopes and monoclonal antibody conjugation procedure and further simplification and ease of use of these procedures; and (3) the apparent safety of single or, in selected cases, multiple administration of MoAbs to humans. The development of radioimmunoscintigraphy or radioimmunodetection has added a significant new dimension to nuclear imaging, and it is very likely to broaden our approach to diagnosis and perhaps therapy of malignant diseases. The indications and limitation of radioimmunoscintigraphy must be clearly outlined to the referring oncologists and surgeons. The unique capability of radiolabeled MoAbs in detecting occult disease, upstaging patients, and, most importantly, changing patient management must be emphasized.
在过去二十年中，单克隆抗体（MoAbs）在癌症诊断和治疗中的体内应用得到了广泛研究。这可能与三个主要因素有关：（1）由科勒和米尔斯坦带来的单克隆抗体制备的显著改进；（2）放射性同位素和单克隆抗体偶联程序的改进以及这些程序的进一步简化和易用性；（3）单剂量或在特定情况下多剂量向人体施用单克隆抗体的明显安全性。放射免疫闪烁显像或放射免疫检测的发展为核成像增添了一个重要的新维度，并且很可能拓宽我们对恶性疾病的诊断方法，甚至治疗方法。必须向转诊的肿瘤学家和外科医生清楚地概述放射免疫闪烁显像的适应症和局限性。必须强调放射性标记单克隆抗体在检测隐匿性疾病、提高患者分期，以及最重要的是改变患者治疗管理方面的独特能力。
